Sagimet Biosciences Inc.
Income Statement
| Line Item | Sep 2023 |
|---|---|
| Revenue | $2.0M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $5.0M |
| SG&A Expense | $4.5M |
| Operating Income | $-7.5M |
| Operating Margin | -372.6% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-6.4M |
| Net Margin | -317.7% |
| EPS (Basic) | $0.00 |
| EPS (Diluted) | $0.00 |
| Shares Outstanding (Basic) | 3.11B |
| Shares Outstanding (Diluted) | 3.11B |
| Dividends Per Share | — |